Preparation of human SET8 monoclonal antibody and its effect on hepatocellular carcinoma cell proliferation, apoptosis and cell cycle
Affiliation:

The Fourth Hospital of Hebei Medical University

  • Article
  • | |
  • Metrics
  • |
  • Reference [15]
  • | | | |
  • Comments
    Abstract:

    Objective To prepare human SET8 monoclonal antibody and explore its effects on the proliferation, apoptosis and cell cycle of hepatoma cells, and evaluate its anti-tumor effect in mouse models of hepatocellular carcinoma. Methods By immunizing mice with human SET8 polypeptide fragment, B cells and myeloma cells were screened and fused to establish hybridoma cell line that secreted SET8 monoclonal antibody stably. The production was expanded by intraperitoneal injection of mice and collection and purification of ascites. The CCK-8, flow cytometry and Western blot were used to analyze the effects of SET8 monoclonal antibody on the proliferation, apoptosis, cell cycle and apoptosis-related protein expression of hepatocellular carcinoma cells. Finally, a mouse model of human hepatocellular carcinoma cell transplantation was constructed to evaluate the inhibitory effect of SET8 monoclonal antibody on tumor growth in vivo. Results Human SET8 monoclonal antibody significantly inhibited the viability of Huh-7 and Mahlavu hepatoma cells at the concentration of 50ug/ml and 100ug/ml, and the higher the concentration, the stronger the inhibitory effect. Flow cytometry analysis showed that compared with the control group, SET8 monoclonal antibody, paclitaxel and their combination treatment significantly increased the apoptosis rate of Mahlavu cells, and the combination group had the best effect. Meanwhile, SET8 monoclonal antibody induced Mahlavu cell cycle arrest in S and G2 phases and reduced G1 phase cells. Western blot analysis showed that the monoclonal antibody increased the expression of apoptosis-related proteins Bax and caspase-3. Further animal experiments showed that SET8 monoclonal antibody alone or in combination with paclitaxel effectively inhibited the proliferation of hepatocellular carcinoma cells in nude mice, and the combination therapy had the most significant effect. Conclusion The prepared human SET8 monoclonal antibody effectively inhibited the proliferation of hepatocellular carcinoma cells, promoted the apoptosis of hepatocellular carcinoma cells, and showed a good anti-tumor effect in animals.

    Reference
    [1] SHARMA R. Descriptive epidemiology of incidence and mortality of primary liver cancer in 185 countries: evidence from GLOBOCAN 2018 [J]. Jpn J Clin Oncol, 2020, 50(12):1370-1379.
    [2] MOHAMMADIAN M, ALLAH BAKESHEI K, MOHAMMADIAN-HAFSHEJANI A. International epidemiology of liver cancer: geographical distribution, secular trends and predicting the future[J]. J Prev Med Hyg, 2020, 61(2):E259-E289.
    [3] ZHENG S, CHAN S W, LIU F et al. Hepatocellular Carcinoma: Current Drug Therapeutic Status, Advances and Challenges. Cancers (Basel) [J]. 2024, 16(8):1582.
    [4] LIU B, ZHANG X, SONG F, et al. A functional single nucleotide polymorphism of SET8 is prognostic for breast cancer[J]. Oncotarget, 2016, 7(23):34277-34287.
    [5] YANG S, GUO H, WEI B, et al. Association of miR-502-binding site single nucleotide polymorphism in the 3''-untranslated region of SET8 and TP53 codon 72 polymorphism with non-small cell lung cancer in Chinese population. Acta Biochim Biophys Sin (Shanghai)[J]. 2014, 46(2):149-154.
    [6] HOU L, LI Q, YU Y, et al. SET8 induces epithelial?mesenchymal transition and enhances prostate cancer cell metastasis by cooperating with ZEB1[J]. Mol Med Rep, 2016, 13(2):1681-1688.
    [7] QI J, CHEN X, WU Q, et al. Fasting Induces Hepatocellular Carcinoma Cell Apoptosis by Inhibiting SET8 Expression[J]. Oxid Med Cell Longev, 2020, 2020:3985089.
    [8] GUO Z, WU C, WANG X, et al. A polymorphism at the miR-502 binding site in the 3''-untranslated region of the histone methyltransferase SET8 is associated with hepatocellular carcinoma outcome[J]. Int J Cancer, 2012, 131(6):1318-1322.
    [9] WU J, QIAO K, DU Y, et al. Downregulation of histone methyltransferase SET8 inhibits progression of hepatocellular carcinoma[J]. Sci Rep, 2020, 10(1):4490.
    [10] MILITE C, FEOLI A, VIVIANO M, et al. Progress in the Development of Lysine Methyltransferase SETD8 Inhibitors[J]. ChemMedChem, 2016, 11(16):1680-1685.
    [11] WU S, WANG W, KONG X, et al Dynamic regulation of the PR-Set7 histone methyltransferase is required for normal cell cycle progression[J]. Genes Dev, 2010, 24(22):2531-2542.
    [12] ABBAS T, MUELLER A C, SHIBATA E, et al. CRL1-FBXO11 promotes Cdt2 ubiquitylation and degradation and regulates Pr-Set7/Set8-mediated cellular migration[J]. Mol Cell, 2013, 49(6):1147-1158.
    [13] ZHANG W, ZHENG X, MENG T, et al. SET protein overexpression contributes to paclitaxel resistance in MCF-7/S cells through PI3K/Akt pathway[J]. J Drug Target, 2017, 25(3):255-263.
    [14] DENG S, BANERJEE S, CHEN H, et al. SB226, an inhibitor of tubulin polymerization, inhibits paclitaxel-resistant melanoma growth and spontaneous metastasis[J]. Cancer Lett, 2023, 555:216046.
    [15] CHIN H G, ESTEVE P O, RUSE C, et al. The microtubule-associated histone methyltransferase SET8, facilitated by transcription factor LSF, methylates α-tubulin[J]. J Biol Chem, 2020, 295(14):4748-4759.
    Related
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation
Share
Article Metrics
  • Abstract:115
  • PDF: 0
  • HTML: 0
  • Cited by: 0
History
  • Received:August 22,2024
  • Revised:October 09,2024
  • Adopted:January 15,2025
Article QR Code